SIGA - Sector: Healthcare---Industry: Biotechnology & Drugs

[la-onda]

Dear Friends of SIGA Technologies,
It is with great pleasure that we announce the initiation of analyst coverage of SIGA Technologies by the firm of Ladenburg Thalman.

Front page highlight statements includes:

* "Initiating coverage of SIGA with a Buy rating and $5.45 price target"
* "SIGA is well positioned to capture a material portion of the 17-fold increase in federal funding for biodefence since FY 2001"
* "We expect SIGA to receive a $100 million procurement contract for ST-246 under Project BioShield as early as Q4 2008"
* "We expect an initial BioShield award to trigger other purchases of ST-246."

While SIGA will not redistribute the report on behalf of Ladenburg, you should note that overall the report does an excellent job of encapsulating the SIGA value proposition.  An excerpt from the report regarding the $5.45 price target is as follows:

"We are modeling revenue and earnings, respectively, of $7.1 million and $(0.22) in FY 2007, $8.1million and $(0.18) in FY 2008, $15.6 million and $(0.35) in FY 2009. We have not modeled a potential procurement award for ST246 into our FY 2008 or FY 2009 revenue projections, however, since the amount awarded would be recorded initially on the balance sheet as deferred revenue until delivery of ST246 is made. SIGA could initially draw down 50% of the award to fund manufacturing scaleup; subsequent draw downs would be based on the achievement of specified milestones.

In our view, SIGA's current $98 million market cap significantly undervalues the near and long term revenue potential of ST246 and affords little to no value to the Company's other product candidates in development. As noted above, we expect SIGA to receive a $100 million procurement contract for ST246 under Project BioShield as early as Q4 2008. Our initial twelve month price target of $5.45 is based on SIGA achieving a trailing P/S multiple of 25x, inline with a basket of small cap peers that also specialize in treatments for infectious disease. Notably, our target of $5.45 equates to a sales multiple of less than 2x the anticipated $100 million contract for ST246."

[la-onda]

SIGA update:
SIGA: Manufacturing of Lead Smallpox Antiviral ST-246 to Begin
Friday , April 04, 2008 09:28ET

By Fain Hughes, [email protected]

SIGA Technologies, Inc. (SIGA) has initiated the activities necessary to produce the NDA registration batches of its lead smallpox antiviral, ST-246. In recent months, SIGA selected, following consultation with the FDA, the final chemical formulation for large-scale production. SIGA has also finalized the market image and packaging of the commercial material.

SIGA has contracted with Albemarle Corporation (ALB) to provide its scale-up and manufacturing services to produce three registration batches in anticipation of the upcoming pivotal safety clinical trial. In order to obtain FDA marketing approval, SIGA must manufacture "registration batches," which are commercial amounts of ST-246 produced in accordance with the FDA's current standards for good manufacturing practices, sometimes called "cGMP."

&

SIGA Advances ST-246 Smallpox Antiviral Development in Europe
Tuesday , April 15, 2008 08:00ET

NEW YORK, Apr 15, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a 'small and medium-sized enterprise' (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a smallpox antiviral and SIGA's lead product candidate. SIGA has also initiated the process for obtaining Marketing Authorization with ST-246 with the EMEA, which is the European equivalent of the United States Food and Drug Administration.

The European Agency for the Evaluation of Medicinal Products (EMEA) established SME as a dedicated office in 2005 to provide special assistance to small and medium-sized enterprises. SME provides qualified companies with scientific advice and protocol assistance in the development of new medical products. SME status also entitles SIGA to certain fee reductions or deferrals, including reduced fees for scientific advice and certain administrative services of the EMEA, and a deferral of the fee payable for an application for marketing authorization.

"Obtaining SME status is a significant achievement in our pursuit of European regulatory approval for ST-246. The SME Office works with small companies like SIGA to assist and provide support throughout the application process. We now have access to advice from the EMEA on the approval process for ST-246 that will allow us to expedite many of the procedures during the approval path. SIGA will continue to work closely with the EMEA in the coming months as it moves forward in its efforts to obtain marketing authorization in Europe for ST-246," Dr. Eric A. Rose, Chief Executive Officer of SIGA Technologies, stated.

In addition, SIGA engaged the SME Office in a pre-submission meeting to discuss development of ST-246 in Europe. The pre-submission meeting with the SME office provided regulatory guidance with respect to the approval process for ST-246 in Europe. SIGA is in the process of scheduling a Scientific Advice Working Party (SAWP) meeting with the EMEA to discuss the development path for ST-246.

Dr. Rose added, "The SAWP meeting will help SIGA construct an appropriate development pathway for ST-246 in Europe since there is currently no European guidance available on development of a drug that cannot be tested for efficacy in human beings due to the lack of a naturally infected population."

chart bullish:

[la-onda]

BO Alert:

SIGA: Volume Spike; 61% > 20-adsv, Stock +11.45%
Thursday , April 17, 2008 15:20ET

This is the 1st VOLUME alert for SIGA in the past 7 calendar days.

Trading for SIGA Technologies Inc (NASDAQ SC: SIGA) has been heavier than usual in today's session. By 15:20 ET, the stock had already traded 236,807 shares via 600 trades. The cumulative volume is 61.16% above its 20-day average of 146,937. Normally the stock experiences around 322 individual trades per session.

So far, today's volume surge has caused a net rise in SIGA's stock price. At the time of this alert, the stock was trading at $3.310, up $0.340 (+11.45%).

One year ago, the Company's shares closed at $5.292. The price has declined more than 37 percent since then.

Over the last 10 trading session SIGA has traded in a range between $2.120 and $3.060 and is currently trading 39.71% below its 52-week high of $5.490 set on April 19,2007 and 85.96% above its 52-week low of $1.780 from March 17,2008.

In the previous 3 sessions, SIGA trading has displayed a positive trend. Closing results have been as follows:

April 16, 2008 --- closed at $2.970 up $0.070 (+2.41%) on 138,300 shares
April 15, 2008 --- closed at $2.900 up $0.056 (+1.97%) on 130,700 shares
April 14, 2008 --- closed at $2.844 up $0.084 (+3.04%) on 85,400 shares

The Company last released news on April 15, 2008:

"SIGA Advances ST-246 Smallpox Antiviral Development in Europe"

[setravis]

NEW YORK, Apr 18, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that its Chief Scientific Officer, Dr. Dennis E. Hruby, is presenting a Distinguished Lecture at the Centers for Disease Control and Prevention (CDC) in Atlanta on Wednesday, April 23, 2008. Dr. Hruby's presentation, entitled "Discovery and Development of a Smallpox Antiviral Drug," outlines the progression of SIGA's anti-orthopoxvirus drug, ST-246, from its discovery in the laboratory through SIGA's recent filing with the U.S. Food and Drug Administration (FDA) in support of an Emergency Use Authorization (EUA) application for the drug.

Commenting on the CDC presentation, Dr. Hruby stated, "We look forward to having a platform such as this to provide an update on the progress we have made with our ST-246 antiviral. We have recently achieved several milestones that are of significant importance, including the submission of our application supporting an EUA, the completion of our multiple ascending dose human clinical trial and initiating the process of obtaining marketing authorization in Europe. The CDC has a very intimate understanding of the seriousness of the smallpox virus and the threat that it poses to global health safety. We think that this forum will provide those attending with a better understanding of how far we have come in the development of ST-246 and the drug's capabilities in the event of a smallpox virus release."

Dr. Hruby will also meet with CDC colleagues to discuss a series of smallpox virus challenge studies in nonhuman primates designed to further define the window of protective efficacy of ST-246. In the past, ST-246 has demonstrated significant antiviral activity against both the monkeypox virus and smallpox virus in primate models of disease.

Dr. Hruby specializes in virology and microbial pathogenesis research, and the use of viral and bacterial vectors to produce recombinant vaccines. He is a member of the American Society of Virology, the American Society for Microbiology and a fellow of the American Academy of Microbiology.

The upcoming smallpox virus challenge studies are of special interest to the CDC and SIGA due to the successful effort by SIGA at CDC's request to help save the life of a 28-month toddler who had contracted a severe case of eczema vaccinatum (CID, 2008:46), which had arisen as a complication from smallpox vaccine administration. The FDA's issuance of a compassionate emergency usage approval at CDC's request allowed the child, who was near death and on the ninth day of hospitalization, to receive ST-246. The child's prompt recovery suggests that the therapeutic window for ST-246 use may extend beyond the onset of disease symptoms.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

SOURCE: SIGA Technologies, Inc.


KCSA Strategic Communications 
Todd Fromer, 212-896-1215 
[email protected] 
or 
Marybeth Csaby, 212-896-1236 
[email protected] 
or 
David Burke, 212-896-1258 
[email protected] 

Copyright Business Wire 2008

[setravis]

The Company recognized revenues from grants and contracts of $1.7 million for the quarter ended June 30, 2008, an increase of approximately 19% compared to same quarter of the prior year. Operating loss for the quarter was $2.1 million, essentially unchanged from the loss incurred in the prior year period. The recognition of a non-cash loss of $1.1 million reflecting an increase of the fair market value of certain rights and warrants to purchase common shares of the Company resulted in a loss per share, on a fully diluted basis, of $0.09 as compared to income of $0.02 for the same period last year.

For the six months ended June 30, 2008, the Company reported revenue of $3.7 million, an increase of approximately 12% as compared to the $3.3 million reported for the six months ended June 30, 2007. Operating loss for the period was $4.1 million, an increase of approximately 6% from the prior year six month period. Net loss per share for the periods ending June 30, 2008 and 2007 were $0.12 and $0.08, respectively. Included in net income was a non-cash gain of approximately $1 million in 2007, reflecting changes in the fair value of rights and warrants to purchase common shares.

Total cash and equivalents and short-term investments at June 30, 2008 totaled $5.4 million as compared to $6.8 million at December 31, 2007.

[la-onda]

again up on good volume 

[setravis]

The Next Million-Dollar Penny Stock
Penny stocks can make you rich. Need proof? Every one of these multi-baggers was, at one time, a penny stock:

Dynamic Materials (Nasdaq: BOOM)
$10.13...Recent Price
553.5%...Five-Year Return


Meridian Bioscience (Nasdaq: VIVO)
$16.90...Recent Price
310.2%...Five-Year Return


True Religion (Nasdaq: TRLG)
$12.16...Recent Price
1,047.2%...Five-Year Return


Sterling Construction
$19.38...Recent Price
396.9%...Five-Year Return


SIGA Technologies (Nasdaq: SIGA)
$4.87...Recent Price
160.4%...Five-Year Return


Video on siga website
have you seen the this video(global impact & Defense)
http://www.siga.com/index.php?ID=72
The average person has no clue what this could do to the the world if this ever happened...


52wk Range: 1.94 - 5.86
Volume: 511,670
Avg Vol (3m): 178,527

Technicals
Last Price Quote is:
11.49%above 13-day MA
21.59%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $184.38 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2009
Last Analyst Rating: N/A

Below the 10 year chart.......

[setravis]

SIGA - Momentum.......

SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases.

Buy any weakness...pull back...dip

52wk Range: 1.94 - 6.33
Volume: 547,192
Avg Vol (3m): 194,379

Technicals
Record Price High

Last Price Quote is:
15.21%above 13-day MA
28.68%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $208.87 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2009
Last Analyst Rating: N/A

[setravis]

A pop this morning...

SIGA Technologies Inc.(NasdaqGM: SIGA)

Real Time 11.88  3.32 (38.79%) 10:31AM EDT

Last Trade: 11.60
Trade Time: 10:16AM EDT
Change:  3.04 (35.51%)
Prev Close: 8.56
Open: 12.21
Bid: 11.55 x 100
Ask: 11.62 x 500
1y Target Est: 10.88
Day's Range: 11.11 - 12.34
52wk Range: 4.83 - 12.34
Volume: 3,459,305
Avg Vol (3m): 280,174
Market Cap: 530.60M
P/E (ttm): N/A
EPS (ttm): -0.25
Div & Yield: N/A (N/A)


•InPlay: SIGA Technologies selected for the procurement of smallpox antiviral drug for the strategic national stockpile; responds to small business size protestBriefing.com(Wed 8:34AM EDT)

8:34AM SIGA Technologies selected for the procurement of smallpox antiviral drug for the strategic national stockpile; responds to small business size protest (SIGA) 8.56 : Co announces that the U.S. Department of Health and Human Services has announced its intention to make an award to co of a contract to deliver 1.7 mln courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to co's status with the Small Business Administration. The base contract is expected to generate revs of ~$500 mln, and the entire contract is expected to generate revs of ~$2.8 bln. The Small Business Administration issues derive from HHS notification to co that Chimerix has filed a small business size protest against co after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. Co intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

[setravis]

.•UPDATE - SIGA says to get $2.8 bln US drug contract; shares jumpat Reuters(Wed 9:44AM EDT)

Wed Oct 13, 2010 9:44am EDT

* Says Dept of Health & Human Services to give contract

* Contract to supply 1.7 mln courses of smallpox drug

* Contract pending small business protest by rival bidder

* Shares jump 44 pct

Oct 13 (Reuters) - Drugmaker SIGA Technologies Inc (SIGA.O) said it expects to get a U.S. government contract worth upto $2.8 billion if all options are exercised, to supply 1.7 million courses of its smallpox antiviral drug for the strategic national stockpile.

SIGA shares jumped 44 percent to a life-time high of $12.34 in early trading Wednesday on Nasdaq.

The contract from the U.S. Department of Health and Human Services is subject to pending resolution of certain issues as a rival bidder has filed a small business size protest against SIGA, the company said in a statement.

The base contract for the drug, codenamed ST-246, is expected to generate about $500 million in revenue, said SIGA, which develops products for use in defense against biological warfare agents.

SIGA also said it was "appropriately qualified" as a small business concern for this procurement, responding to a small business size protest filed by Chimerix Inc, an unsuccessful bidder.

The company said it intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

The drug works by blocking the ability of the virus to spread to other cells. It was given the fast-track status by the U.S. health regulators, according to SIGA website.

SIGA's shares, which have risen 25 percent since it completed successful human safety trial on the drug in June, were up $3.39 at $11.95 in morning trade. (Reporting by Shravya Jain in Bangalore; Editing by Gopakumar Warrier)

[setravis]

SIGA  SIGA Selected for the Procurement of Smallpox Antiviral... 


NEW YORK, Oct 13, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. (SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the U.S. Department of Health and Human Services (HHS) has announced HHS's intention to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to SIGA's status with the Small Business Administration. The award relates to a Request for Proposal issued by HHS's Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35). The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.

The Small Business Administration issues noted above derive from HHS notification to SIGA that Chimerix, Inc. (Chimerix) has filed a small business size protest against SIGA after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. HHS designated the proposed contract as a small business set-aside at the time of the original solicitation in March 2009. SIGA intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, stated, "We are very proud that HHS has selected our groundbreaking drug, ST-246(R), for this important acquisition and believe that SIGA appropriately qualified as a small business concern for this procurement."

Details of HHS's March 11, 2009 request for proposal and subsequent amendments can be found on the Federal Business Opportunities website at www.fbo.gov/index?s=opportunity&mode=form&id=61e7acbe316f2c52bfe0cc8c4b4852fd&tab=core&_cview=1 . SIGA expects the proposed contract to be executed following resolution of the Chimerix protest; however, there can be no assurance concerning the outcome of the small business size protest.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/ .

The SIGA Technologies, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding SIGA's ability to offer its products for sale to the U.S. government and statements regarding execution of the contract described above or the timing or outcome of the pending protest. Statements other than statements of historical fact are forward-looking statements, and may be identified by, among other things, forward-looking language such as the words or phrases "expect," "intend," "believe," "anticipate," "estimate," "may," "project," "scheduled to," "seek," "should," "would," "will be," "will continue," "will likely result," "targeted," or the negative of those terms, or other similar words and phrases or by discussions of intentions or plans. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete the procurement set forth in its solicitation for the acquisition of smallpox antiviral for the strategic national stockpile, or may complete it on different terms, (ix) the risk that the pending protest or another future protest may cause a contract award to us through the RFP process to be delayed or overturned, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, and (xi) the effect of federal, state, and foreign regulation on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at http://www.sec.gov . Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.


CONTACT:  KCSA Strategic Communications
Todd Fromer
212-896-1215
[email protected]
Marybeth Csaby
212-896-1236
[email protected]

[setravis]

SIGA Tech - biotech focusing on defense against biological warfare agents. Above the 50-day. MACD bottoming.


Technicals
Record Price High !!!
Most Actives
Record Price Break Out !!!
Gap Up
Percentage Gainer
Price Gainer

Last Price Quote is:
41.19%above 13-day MA
44.98%above 50-day MA
RS Rating: 93 

[setravis]

SIGA soars on government contract...

SIGA, three days ago received a contract from the government that could be worth conceivably up to $2.8bb for its smallpox antiviral product.

This potentially $2.8bb contract for SIGA is very significant for PIP, which is engaged in a lawsuit with SIGA that could be worth billions to PIP. SIGA produces the smallpox antiviral ST-246, which was just awarded the government contract. SIGA and PIP were at one point, back in 2006, planning on merging. As part of the merger agreement, it was determined that if the merger did not go through that PIP would be able to exclusively license development and marketing rights for ST-246. The merger did not go through, BUT PIP never got the license agreement. Hence, PIP sued SIGA. In my original article I asserted that this was a catalyst for PIP to go higher but it was hard to quantify that catalyst since we didn't know what sorts of revenues ST-246 could generate.

Well, now we can quantify it. Potential revenues are $2.8bb. Pharmathene is a $70mm market cap company. On the basis of this contract alone, Pharmathene would potentially make up to a billion dollars in cash earnings. So what is going on with the lawsuit ?

In July a judge reviewed SIGA's motion to dismiss the case. Note, this is the same judge that rejected an earlier motion to dismiss in January, 2008. The judge is expected to rule on the motion by the end of this month and then the court is expected to go to trial in January. I've thoroughly reviewed the transcript from July. The basic point that SIGA was making in court is that they had no idea how good (or bad) ST-246 was going to do so there was no way to assign a number to damages. The judge, though, basically made the point (I am paraphrasing) that if that were the case then anyone could walk away from any contract if the future potential of that contract was still unknown. He then implied that should the trial go forward and SIGA were to lose then he, the judge, would have the power to determine what the damages were.

However, lets forget that he said all of that. Because we now know what potential damages could be. And the number is in the billions for a $70mm market cap company.

Can the judge dismiss the case? I don't think he will. Specifically he said, "Everybody should proceed on the assumption that there is no way that I am changing the trial date." He then set a trial date for January 3, 2011.

Given that the trial is probably going through and that there is a very reasonable chance SIGA could lose (and lose billions in revenues as a result), the best result for SIGA would be to settle the case before a trial. My guess is they will settle by January. In every scenario, a settlement would benefit shares of PIP.

I have no idea what sorts of terms PIP would accept but here are some possible settlements:

A) A cash settlement between $100-400mm. Since PIP has a market cap of $70mm, this would create anywhere from a $5 to $10 per share value for PIP.

B) An ongoing royalty of 20-30% on sales of ST-246. Again, this would instantly catapult the stock up to $10+.

Most likely a settlement would be some combination of the above two (e.g. $150mm in cash, 5% royalty, etc).

On this one catalyst I think PIP is potentially a $7 - $12 stock, particularly given the two events that have occurred since my article first appeared: the court appearance, and the contract award for ST-246.

While I think this catalyst alone is enough to quadruple the stock price I don't think its the main fundamental catalyst for the company.

The main catalyst is the product that Pharmathene produces, a next-generation vaccine for Anthrax. According to this report on a military website Anthrax is considered the "DOD's Number one biological threat". The US is required to have a stockpile of 75 million doses of vaccine. Right now, the only approved supplier of doses of vaccine is EBS, which has a long-approved first-generation vaccine that requires 5 doses over 18 months and costs $120 per dose. PIP's second-generation vaccine requires 3 doses over 60 days and costs about $45 a dose, according to Eric Richman, the CEO of Pharmathene. EBS's vaccine uses live anthrax to make the vaccine, which increases the cost of and loses scalability versus a second-generation version. There are many problems with the older generation (35 years old) Anthrax vaccine from EBS which is why the government has recently approved $80mm in funding for Pharmathene to continue their work (EBS tried to protest this funding but BARDA threw out their protest).

What is the fundamental value of this vaccine? I'll quote my earlier article: "Assuming Pharmathene can build out the manufacturing processes in three years and their experimental studies continue to produce good results, a dose would cost $45. Since the only customer is the government, this essentially eliminates sales and marketing costs as well as research and development costs. Most biotech firms (think: DNDN, GENZ, GILD, HGSI) enjoy 85% margins on their products because they have to absorb those costs. PIP won't have to — although it is beholden to a single customer. Let's assume 20% net margins, or approximately $10 per dose. Let's assume the government buys 25 million of its 75 million dose requirement from PIP (remember, there is only one other competitor). That means $250 million in earnings in three years.

This alone could easily justify a stock jump to the $7-10 level, or even significantly higher. Also, once the U.S. starts buying, there will be demand from outside the country. This does not factor in significant government funding for several other products including Protexia, a nerve gas vaccine." Note that PIP does not need FDA approvals to start selling the to the government but that they have already tested for safety (no issues) and efficacy in animals (depending on the test, they are 85-100% effective).

So $5-10 in value from the SIGA lawsuit and another $7-10 from their Anthrax vaccine leaves PIP with a $14-$22 stock from these levels, much how SIGA has gone from below $2 to $13 in the past 4 years and EBS has gone from $5 to 20 in the past 3 years. Given these two completely separate catalysts I also think downside is minimal.

Disclosure: Long PIP

[setravis]

Another pop for SIGA.......
not really sure of the numbers, but with a contract, and projections of anywhere from $500 million to $2.8 billion, the game has changed quite a bit.

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
32.19%above 13-day MA
57.53%above 50-day MA
RS Rating: 96 

[setravis]

The Next Million-Dollar Penny Stock
Penny stocks can make you rich. Need proof? Every one of these multi-baggers was, at one time, a penny stock:

Dynamic Materials (Nasdaq: BOOM)
$10.13...Recent Price
553.5%...Five-Year Return


Meridian Bioscience (Nasdaq: VIVO)
$16.90...Recent Price
310.2%...Five-Year Return


True Religion (Nasdaq: TRLG)
$12.16...Recent Price
1,047.2%...Five-Year Return


Sterling Construction
$19.38...Recent Price
396.9%...Five-Year Return


SIGA Technologies (Nasdaq: SIGA)
$4.87...Recent Price
160.4%...Five-Year Return


Video on siga website
have you seen the this video(global impact & Defense)
http://www.siga.com/index.php?ID=72
The average person has no clue what this could do to the the world if this ever happened...

SIGA SIGA to Discuss Third Quarter Results of Operations on Novem... 


NEW YORK, Oct 29, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. (SIGA, Trade ), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report third quarter 2010 results on Tuesday, November 2, 2010.

Management will host a conference call and simultaneous webcast to discuss the results of operations and provide an update on recent business developments at 4:30 P.M. ET on Tuesday, November 2, 2010. Participants should call (877) 564-1219 (United States/Canada) or (973) 638-3429 (International) and request the SIGA call or provide confirmation code 22244336. A live broadcast of the call will be available on the Company's website at www.SIGA.com under the 'Events & Presentations' tab in the Investor Relations section.

A replay of the call will be available approximately two hours after the call and will be accessible until 11:59 p.m. on Tuesday, November 9, 2010. To listen to the replay, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter the pass code 22244336. The webcast of the event will also be archived on the Company's website for one year under the 'Events & Presentations' tab in the Investor Relations section.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/ .

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.


CONTACT:  KCSA Strategic Communications
Todd Fromer
212-896-1215
[email protected]
Marybeth Csaby
212-896-1236
[email protected]